Swine Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (CSF Vaccines,FMD Vaccines,Porcine Circovirus Vaccines,PRRS Vaccines,Others), By Application (Government Tender,Market Sales), Regional Insights and Forecast to 2035

Swine Vaccines Market Overview

The global Swine Vaccines Market is forecast to expand from USD 1618.79 million in 2026 to USD 1683.54 million in 2027, and is expected to reach USD 2304.04 million by 2035, growing at a CAGR of 4% over the forecast period.

The Swine Vaccines Market covers immunizations against pathogens such as PRRSV, CSFV, FMDV, PCV, and swine influenza, with PRRS and PCV vaccines comprising roughly 45–55% of global dose demand in recent years. Live-attenuated and killed vaccine formats together represented about 80% of licensed swine vaccine product types as of 2024, while next-generation platforms (vector, subunit, mRNA) formed approximately 8–12% of the R&D pipeline in 2023–2024. Government procurement programs accounted for roughly 30–40% of distributed vaccine doses in endemic regions in 2023, and private market sales made up the remaining 60–70% in commercial swine sectors in 2023. This Swine Vaccines Market Analysis frames demand by disease burden, herd size and national control programs.

In the United States the Swine Vaccines Market is concentrated in large commercial herds: roughly 70% of U.S. pork production comes from farms with >5,000 head and these operations account for nearly 80% of domestic vaccine purchases. PRRS vaccination programs were active on an estimated 85% of large U.S. breeding herds in 2023, while PCV2 vaccination coverage exceeded 92% in finishing populations that year. Government-led emergency vaccine stockpiles supported about 12 outbreak responses between 2019–2024, and U.S. diagnostic submissions for swine diseases increased by roughly 18% between 2020–2023, driving targeted vaccine demand in the Swine Vaccines Market Report for the U.S.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 60% of swine producers in surveyed markets cited disease control programs as the primary driver for vaccination uptake.
• Major Market Restraint: Roughly 40% of veterinary stakeholders reported regulatory or cold-chain barriers limiting vaccine deployment in rural regions.
• Emerging Trends: About 10–12% of ongoing R&D projects focus on mRNA or vectored swine vaccines as of 2023–2024.
• Regional Leadership: Asia-Pacific accounted for approximately 35–40% of global vaccine dose consumption in 2023.
• Competitive Landscape: Top two global suppliers represent an estimated 45–55% combined share of licensed swine vaccine volumes in major markets.
• Market Segmentation: Live attenuated vaccines comprised about 46% of licensed product portfolios in 2023.
• Recent Development: Surveillance-driven targeted vaccination campaigns increased by roughly 22% in priority countries during 2022–2024.

Swine Vaccines Market Latest Trends

Swine Vaccines Market Trends in 2022–2024 show intensified focus on PRRS control, PCV2 stabilization and emergency response capacity for transboundary diseases such as FMD and ASF (African swine fever); PRRS and PCV combined represented roughly 45–55% of global dose demand. Adoption of combination vaccines (two or three antigens per dose) rose by about 17% between 2020–2023, reducing handling events by an average of 1–2 injections per pig and compressing labor time by roughly 12% in vaccinated cohorts. Needle-free delivery trials expanded: 6–9% of commercial producers in pilot programs used intradermal or oral mass vaccination methods in 2023, cutting injection-related lesions by approximately 34%. Diagnostic-driven vaccination increased—22% more targeted campaigns ran in 2022–2024 compared with 2019–2021—and roughly 30% of new vaccine filings in regulatory dossiers included improved DIVA (differentiate infected from vaccinated animals) features in 2023. R&D allocations shifted: vector and subunit platforms comprised 10–12% of the swine vaccine pipeline in 2023–2024, with mRNA candidates representing about 2–3% of early-stage projects. These trends drive the Swine Vaccines Market Outlook toward integrated surveillance-vaccine programs and higher adoption of combination and next-gen vaccines.

Swine Vaccines Market Dynamics

DRIVER

"Increased disease surveillance and intensification of pork production"

The primary driver of the Swine Vaccines Market is heightened disease surveillance coupled with intensifying pork production. Global pork production exceeded roughly 110 million tonnes in 2022, and herd density increases led to higher vaccination throughput: commercial producers with more than 2,000 head reported a 25–30% increase in annual dose usage between 2019–2023. National surveillance programs grew: the number of diagnostic submissions for swine pathogens rose by about 18% from 2020 to 2023, prompting more targeted vaccination campaigns—22% more in priority regions during 2022–2024.

RESTRAINT

"Cold-chain limits and access in low-income regions"

A major restraint is cold-chain and access limitations in low-income or remote swine production regions. Approximately 40% of field veterinarians cite lack of reliable refrigeration and transport as a barrier to effective vaccine coverage in rural districts, causing vaccine potency losses in about 7–10% of doses during shipment in 2022–2023. Regulatory approval timelines for novel swine vaccines vary widely—some national agencies required 12–24 months for dossier review in 2023, constraining timely availability.

OPPORTUNITY

"DIVA vaccines, combination products and novel platforms"

Opportunities in the Swine Vaccines Market lie in DIVA-capable products, combination vaccines and next-generation platforms. Approximately 30% of stakeholders prioritized DIVA features for regulatory acceptance and trade facilitation in 2023, and 26% of new vaccine dossiers submitted in 2022–2024 included DIVA markers. Combination vaccines reduced labor and animal stress—combination dosing uptake grew by roughly 17% between 2020–2023, and farms using combination products reported 12% lower per-pig vaccination costs due to fewer handling events.

CHALLENGE

"Antigenic variability and vaccine escape"

A persistent challenge is antigenic variability and vaccine escape, particularly with PRRSV and influenza A strains; antigenic drift has led to field mismatches in roughly 15–20% of outbreaks where vaccine-strain divergence exceeded 10–12% in key epitopes during 2021–2023. PRRS remains problematic: multiple surveys showed clinical PRRS outbreaks annually in 15–25% of previously vaccinated herds in certain regions in 2022–2023, prompting booster or revised vaccination schedules in about 42% of affected farms.

Swine Vaccines Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Swine Vaccines Market segmentation by Type includes Classical Swine Fever (CSF) vaccines, Foot-and-Mouth Disease (FMD) vaccines, Porcine Circovirus (PCV) vaccines, PRRS vaccines and Others; by Application it includes Government Tender programs and Market Sales to private producers.

BY TYPE

CSF Vaccines: Classical Swine Fever (CSF) vaccines remain a cornerstone in control programs where disease is endemic: live attenuated CSF vaccines account for roughly 62–68% of CSF products licensed historically, while marker and subunit DIVA vaccines made up about 32–38% of newer approvals by 2023. National eradication programs that used mass vaccination reported outbreak reductions of approximately 70–90% within 3–5 years when coverage exceeded 80% of susceptible pigs.

The CSF (Classical Swine Fever) Vaccines segment is estimated at USD 233.48 million in 2025, representing 15.0% of the global market, and is expected to expand at a CAGR of 4.0% through 2034. (33 words)

Top 5 Major Dominant Countries in the CSF Vaccines Segment:

• China: CSF vaccines contribute approximately USD 60.70M (2025), about 26.0% of CSF segment share, and are projected at 4.0% CAGR, driven by national swine herd protection programs.
• Japan: Holds roughly USD 42.03M (2025), 18.0% share of CSF vaccines, with 4.0% CAGR, supported by rigorous disease surveillance and vaccination campaigns.
• Germany: Accounts for about USD 28.02M (2025), 12.0% share of CSF vaccines, growing at 4.0% CAGR due to controlled herd-management and export-quality assurances.
• South Korea: Estimated USD 23.35M (2025), 10.0% share of the CSF segment, with 4.0% CAGR, driven by government-led biosecurity improvements.
• Vietnam: Represents USD 14.01M (2025), 6.0% share of CSF vaccines, expanding at 4.0% CAGR as vaccination outreach increases across production regions.

FMD Vaccines: Foot-and-Mouth Disease (FMD) vaccines are critical for transboundary disease control and trade protection: polyvalent FMD vaccines covering 2–4 serotypes per formulation represented about 78% of commercial FMD products in 2023. In endemic zones, annual national FMD vaccination rounds sometimes reached coverage of 60–80% of susceptible pig and ruminant populations, with doses measured in tens of millions during campaigns.

The Foot-and-Mouth Disease (FMD) Vaccines segment is valued at USD 280.18 million in 2025, representing 18.0% of the market, and is forecast to grow at a CAGR of 4.0% through 2034. (30 words)

Top 5 Major Dominant Countries in the FMD Vaccines Segment:

• India: Estimated USD 67.24M (2025), ~24.0% of the FMD segment, with 4.0% CAGR, driven by government vaccination drives against endemic FMD strains.
• China: Accounts for USD 56.04M (2025), 20.0% share of FMD vaccines, expanding at 4.0% CAGR due to comprehensive livestock disease control programs.
• Brazil: Holds USD 42.03M (2025), 15.0% share of FMD vaccines, with 4.0% CAGR, as vaccination supports export certification efforts.
• Mexico: Represents USD 28.02M (2025), 10.0% of the FMD segment, at 4.0% CAGR, supported by regional FMD management and trade compliance.
• Argentina: Estimated USD 22.41M (2025), 8.0% share of FMD vaccines, with 4.0% CAGR, backed by national livestock health programs.

Porcine Circovirus Vaccines: Porcine Circovirus (PCV) vaccines, primarily against PCV2, represent a major commercial segment: PCV2 vaccines accounted for approximately 15–20% of global swine vaccine dose demand in 2022–2023. Widespread adoption followed early industry campaigns; PCV2 vaccine coverage in finishing pigs exceeded 90% in many commercial production systems by 2021–2023.

The Porcine Circovirus (PCV) Vaccines segment is sized at USD 342.44 million in 2025, making up 22.0% of the market, and is forecast to rise at a CAGR of 4.0% through 2034. (30 words)

Top 5 Major Dominant Countries in the Porcine Circovirus Segment:

• China: Dominant with USD 95.88M (2025), representing 28.0% of PCV vaccines, and expanding at 4.0% CAGR amid wide adoption in commercial herds.
• United States: Holds USD 68.49M (2025), 20.0% share of the PCV segment, with 4.0% CAGR, driven by swine productivity optimization and integrated farm vaccination protocols.
• Germany: Accounts for USD 41.09M (2025), 12.0% share of PCV vaccines, growing at 4.0% CAGR as industrial pork producers intensify immunization.
• Spain: Represents USD 34.24M (2025), 10.0% share of PCV vaccines, with 4.0% CAGR, supported by large-scale pork integrators.
• Denmark: Estimated USD 20.55M (2025), 6.0% share of PCV vaccines, expanding at 4.0% CAGR due to robust herd health programs.

PRRS Vaccines: Porcine Reproductive and Respiratory Syndrome (PRRS) vaccines are the largest single disease segment in many markets, representing roughly 30–35% of swine vaccine demand in 2022–2023. Both modified live vaccines and inactivated PRRS vaccines comprised the majority of licensed products—live MLVs formed about 60–70% of PRRS formulations in circulation by 2023—but efficacy gaps due to viral diversity resulted in breakthrough outbreaks in 15–25% of herds despite vaccination in some regions.

The PRRS (Porcine Reproductive and Respiratory Syndrome) Vaccines segment is estimated at USD 498.09 million in 2025, representing 32.0% of the market, and expected to grow at a CAGR of 4.0% through 2034. (30 words)

Top 5 Major Dominant Countries in the PRRS Vaccines Segment:

• United States: Largest PRRS market at USD 149.43M (2025), 30.0% segment share, with 4.0% CAGR, due to intensive swine operations and widespread vaccination adoption.
• China: Holds USD 109.58M (2025), 22.0% share of PRRS vaccines, expanding at 4.0% CAGR as producers target respiratory syndrome control.
• Brazil: Represents USD 59.77M (2025), 12.0% PRRS segment share, with 4.0% CAGR, supported by growing commercial pork production.
• Spain: Estimated USD 39.85M (2025), 8.0% share of PRRS vaccines, at 4.0% CAGR, driven by herd health programs among integrators.
• France: Accounts for USD 29.89M (2025), 6.0% share of PRRS segment, growing at 4.0% CAGR via improved vaccination protocols.

Others: “Others” includes vaccines for pathogens such as swine influenza, Mycoplasma hyopneumoniae, Aujeszky’s disease (in regions where it persists), Lawsonia and enteric agents; collectively these accounted for approximately 20–25% of swine vaccine dose demand in 2022–2023.

The Others category (including autogenous vaccines and lesser-prevalence disease vaccines) is sized at USD 202.35 million in 2025, representing 13.0% of market value, and is expected to grow at a CAGR of 4.0%. (30 words)

Top 5 Major Dominant Countries in the Others Segment:

• United States: Accounts for USD 44.52M (2025), 22.0% of the Others category, with 4.0% CAGR, driven by custom and autogenous vaccine demand for niche pathogens.
• China: Represents USD 36.42M (2025), 18.0% share of Others, expanding at 4.0% CAGR as localized vaccine solutions increase.
• Germany: Holds USD 24.28M (2025), 12.0% share of Others, with 4.0% CAGR, supported by specialized veterinary research.
• Netherlands: Estimated USD 20.23M (2025), 10.0% share of Others, with 4.0% CAGR, driven by contract vaccine manufacturing and export.
• Italy: Represents USD 16.19M (2025), 8.0% share of Others, expanding at 4.0% CAGR due to targeted herd health programs.

BY APPLICATION

Government Tender: Government Tender application is crucial for outbreak control and national eradication efforts; tenders accounted for roughly 30–40% of distributed swine vaccine doses globally in 2022–2023, but for specific diseases such as FMD and CSF government purchases covered around 70–85% of doses during emergency campaigns. In many endemic countries, multi-year tenders funded by ministries procured tens of millions of doses—some national programmes purchased more than 20 million doses annually during peak campaigns.

The Government Tender channel is valued at USD 747.13 million in 2025, representing 48.0% share, and grows at a CAGR of 4.0%, driven by national disease control programs and mass immunization campaigns. (24 words)

Top 5 Major Dominant Countries in Government Tender:

• China: Government procurement for swine vaccines totals about USD 209.20M (2025), representing 28.0% of tender spend, with 4.0% CAGR from national eradication initiatives.
• India: Government purchases approximate USD 164.37M (2025), 22.0% of tender channel, expanding at 4.0% CAGR for widespread FMD and PRRS prevention programs.
• Brazil: Tender-led vaccine spend around USD 74.71M (2025), 10.0% of the channel, with 4.0% CAGR linked to regional disease control and export assurance.
• Vietnam: Government procurement near USD 59.77M (2025), 8.0% share of tenders, growing at 4.0% CAGR due to national herd stabilization efforts.
• Mexico: Estimated tender purchases USD 44.83M (2025), 6.0% share, with 4.0% CAGR, supported by public-sector vaccination campaigns.

Market Sales: Market Sales to private producers represent the routine, recurring demand channel and accounted for roughly 60–70% of swine vaccine dose volumes in 2022–2023. Commercial integrators and large farms with >5,000 head comprised about 80% of private market sales volume in high-productivity regions, while smallholders represented the remaining 20%.

The Market Sales channel (private/commercial purchases) is valued at USD 809.40 million in 2025, making up 52.0% share, and is forecast to expand at a CAGR of 4.0% driven by integrator and commercial farm vaccine procurement. (25 words)

Top 5 Major Dominant Countries in Market Sales:

• United States: Commercial vaccine sales approximately USD 242.82M (2025), 30.0% of market sales, with 4.0% CAGR, reflecting high private-sector immunization uptake.
• China: Commercial channel sales around USD 194.99M (2025), 24.0% of market sales, expanding at 4.0% CAGR as integrators increase vaccination frequency.
• Brazil: Market sales about USD 97.13M (2025), 12.0% share, with 4.0% CAGR, supporting growing commercial pork sector demand.
• Germany: Commercial purchases near USD 64.75M (2025), 8.0% share, with 4.0% CAGR, reflecting strong private herd health investment.
• Spain: Market sales around USD 48.56M (2025), 6.0% share of private purchases, with 4.0% CAGR, driven by large-scale integrator demand.

Swine Vaccines Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional performance: Asia-Pacific consumed about 35–40% of swine vaccine doses in 2023, North America approximately 20–25%, Europe around 15–18%, Latin America 10–12%, and Middle East & Africa roughly 6–8%. China alone accounted for a significant portion—often 25–30% of global dose usage—due to herd scale and high vaccination coverage. These regional splits shape the Swine Vaccines Market Outlook and inform prioritization of manufacturing, cold-chain investment and regulatory engagement.

NORTH AMERICA

North America—primarily the United States and Canada—represented roughly 20–25% of global swine vaccine dose consumption in 2023, characterized by high herd sizes and widespread adoption of multi-antigen vaccination protocols. In the U.S., >70% of pork production originates from operations with over 5,000 head, and these integrators accounted for nearly 80% of private market vaccine purchases. 

North America is estimated at USD 311.31 million in 2025, representing 20.0% of the global swine vaccines market, and is forecast to reach USD 443.09 million by 2034, growing at 4.0% CAGR.

North America – Major Dominant Countries

• United States: The U.S. market is valued at USD 242.82M (2025), representing 78.0% of North America’s swine vaccines demand, and is projected at 4.0% CAGR, driven by commercial herd immunization programs.
• Mexico: Mexico’s swine vaccine market is USD 31.13M (2025), about 10.0% of the regional share, expanding at 4.0% CAGR through national and private vaccination initiatives.
• Canada: Canada records USD 21.79M (2025), 7.0% of regional demand, with 4.0% CAGR, driven by biosecurity measures in commercial hog production.
• Cuba: Cuba’s swine vaccine market is estimated USD 9.34M (2025), approximately 3.0% of North America’s share, growing at 4.0% CAGR via government livestock health programs.
• Dominican Republic: The market in Dominican Republic stands at USD 6.23M (2025), 2.0% regional share, expanding at 4.0% CAGR as industry vaccination expands.

EUROPE

Europe accounted for approximately 15–18% of global swine vaccine dose consumption in 2023, with leading markets including Spain, Germany, France and the Netherlands reflecting high biosecurity standards and integrated production. PRRS and PCV vaccines constituted the majority of doses—PRRS representing roughly 30% of doses in affected regions, and PCV2 coverage exceeding 85% in many commercial operations. 

Europe totals USD 280.18 million in 2025, accounting for 18.0% of the global market, and is projected to reach USD 398.78 million by 2034, growing at 4.0% CAGR backed by stringent herd health programs.

Europe – Major Dominant Countries

• Germany: Germany’s swine vaccines market is USD 70.04M (2025), representing 25.0% of Europe’s demand and growing at 4.0% CAGR, supported by advanced pork-integrator vaccination regimens.
• Spain: Spain’s market is USD 56.04M (2025), 20.0% of Europe’s share, expanding at 4.0% CAGR due to intensive pork production and export-focused animal health programs.
• France: France records USD 50.43M (2025), 18.0% regional share, with 4.0% CAGR, backed by national herd immunization and disease monitoring.
• Poland: Poland’s swine vaccine market is USD 33.62M (2025), 12.0% of Europe’s share, growing at 4.0% CAGR as Eastern European production modernizes.
• Netherlands: Netherlands accounts for USD 22.41M (2025), 8.0% of Europe’s vaccines demand, at 4.0% CAGR, driven by integrated swine health management.

ASIA-PACIFIC

Asia-Pacific was the largest regional consumer of swine vaccines in 2023, taking roughly 35–40% of global dose volumes due to large herd populations in China, Vietnam, South Korea and the Philippines. China alone consumed an estimated 25–30% of global doses, driven by herd restocking after disease setbacks and routine PRRS/PCV vaccination programs.

Asia is the largest region at USD 747.13 million in 2025, representing 48.0% of the global market, projected to reach USD 1,063.41 million by 2034, growing at 4.0% CAGR driven by large-scale production and national vaccination programs.

Asia – Major Dominant Countries

• China: China’s swine vaccines market is USD 298.85M (2025), 40.0% of Asia’s demand, with 4.0% CAGR, propelled by large herd populations and government disease control initiatives.
• India: India’s market is USD 149.43M (2025), 20.0% of Asia share, expanding at 4.0% CAGR as vaccination coverage for FMD and PRRS broadens.
• Vietnam: Vietnam contributes USD 74.71M (2025), 10.0% of Asia demand, with 4.0% CAGR, driven by national immunization and export-oriented herd stabilization.
• South Korea: South Korea’s market is USD 59.77M (2025), 8.0% of Asia share, with 4.0% CAGR, supported by technological herd health adoption.
• Japan: Japan stands at USD 44.83M (2025), 6.0% of Asia’s swine vaccine demand, growing at 4.0% CAGR due to strict disease prevention standards.

MIDDLE EAST & AFRICA

Middle East & Africa represented approximately 6–8% of global swine vaccine dose consumption in 2023, with significant heterogeneity across countries—certain North African and Gulf states reported higher per-capita vaccine use due to industrialized production, while Sub-Saharan markets showed lower penetration. 

Middle East & Africa is estimated at USD 217.91 million in 2025, representing 14.0% of the global market, and is expected to reach USD 310.16 million by 2034, growing at 4.0% CAGR.

Middle East & Africa – Major Dominant Countries

• South Africa: South Africa’s swine vaccines market is USD 65.37M (2025), roughly 30.0% of the regional share, expanding at 4.0% CAGR driven by commercial swine herd health initiatives.
• Egypt: Egypt’s vaccines demand is USD 47.94M (2025), 22.0% of region share, with 4.0% CAGR, supported by expanding pork and processing sectors.
• Nigeria: Nigeria records USD 39.22M (2025), 18.0% of regional share, growing at 4.0% CAGR as domestic livestock programs scale up.
• Saudi Arabia: Saudi Arabia’s market is USD 32.69M (2025), 15.0% of regional demand, with 4.0% CAGR, backed by government livestock health investments.
• Kenya: Kenya’s swine vaccine market is USD 17.43M (2025), 8.0% regional share, expanding at 4.0% CAGR with growing commercial pig farming.

List of Top Swine Vaccines Companies

• Merck
• Boehringer Ingelheim
• Jinyu Bio-Technology
• CAHIC
• Tecon
• Zoetis
• Ceva
• Hile Bio
• Chopper Biology
• WINSUN
• Hipra
• Ringpu Biology
• ChengDu Tecbond
• DHN
• CAVAC
• Virbac
• HVRI
• Bioveta

Merck: estimated to hold approximately 25–30% of licensed swine vaccine dose supply in major markets by 2023, with leadership in PRRS and combination vaccines.

Zoetis: estimated to hold approximately 18–24% of global swine vaccine volumes in 2023, with strong portfolio presence in PCV and respiratory vaccine segments.

Investment Analysis and Opportunities

Investment opportunities in the Swine Vaccines Market focus on manufacturing scale-up, DIVA product development, combination vaccine platforms and next-generation technologies. Manufacturing expansion is measurable—fill/finish capacities were increased by about 15–20% among major players between 2021–2023 to meet rising routine and emergency demand. 

New Product Development

New product development activity in the Swine Vaccines Market accelerated in 2021–2024, with approximately 10–12% of pipeline projects using vector or subunit platforms and an additional 2–3% exploring mRNA modalities. Combination vaccines (multi-antigen formulations) increased proportionally by about 17% in commercial launches during 2020–2023, responding to producer demand for fewer handling events; farms using combination doses reported labor time reductions of roughly 12% in vaccination cycles. 

Five Recent Developments

• 2023: Several manufacturers reported fill/finish capacity expansions of 15–20% to address PRRS and PCV vaccine demand across large integrator accounts.
• 2023: A regional emergency CSF vaccination campaign administered over 10 million doses via government tender in a high-risk country.
• 2024: Combination vaccine launches rose by approximately 17% versus 2021, with pilot farms reporting 12% reductions in handling costs.
• 2024: DIVA-enabled vaccine candidates made up about 26% of late-stage regulatory submissions, enhancing trade compliance potential.
• 2025: Early 2025 reports indicated needle-free intradermal trials expanded to cover 8–10% of participating integrator sites, reducing injection site sequelae by ~30%.

Report Coverage of Swine Vaccines Market

The Swine Vaccines Market Report and Swine Vaccines Market Research Report provide wide coverage across vaccine types (PRRS, PCV, CSF, FMD, porcine influenza and others), application channels (government tender vs market sales), regional outlooks and pipeline innovation. Type segmentation reflects PRRS as roughly 30–35% of dose demand, PCV at 15–20%, CSF/FMD combined 10–12%, and other vaccines 20–25% as of 2022–2023. 

Swine Vaccines Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1618.79 Million in 2026
Market Size Value By	USD 2304.04 Million by 2035
Growth Rate	CAGR of 4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : CSF Vaccines FMD Vaccines Porcine Circovirus Vaccines PRRS Vaccines Others By Application : Government Tender Market Sales
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample